David Johnson

• T  +44 (0)20 7090 3385 (Direct line)
• E  david.johnson@slaughterandmay.com

• London 
• One Bunhill Row, London, EC1Y 8YY

David advises on a wide range of corporate and commercial transactions. He has extensive experience in public and private M&A transactions and equity financings. He worked in Schroders' UK corporate finance division for a year and advises several investment banks in London on corporate finance matters.

David acts for a number of listed companies, including GlaxoSmithKline, Punch Taverns, Spirit Pub Company and Whitbread.

His significant transactions include advising:

• Punch Taverns on the demerger of its Spirit business to form Spirit Pub Company PLC
• GlaxoSmithKline on various transactions including its: acquisition of Maxinutrition from Darwin Private Equity, its agreement with Pfizer to create ViiV, a specialist HIV company with proforma combined sales of £1.6 billion and its EUR 515 million acquisition of the marketed product portfolio of UCB S.A. in various jurisdictions
• RBS Equity Finance on its acquisitions of Whiteaway Laidlaw Bank Limited, Commercial First and Link Loans
• Goldman Sachs on the offers for Paladin Resources, Xansa and Venture Production

David is named as a leading individual in the 'Corporate/M&A: High-end Capability' and 'Life Sciences: Transactional' sections of Chambers UK, 2012. He is also listed for 'Corporate/M&A' in Chambers Global, 2011 and for 'Corporate/M&A: High-end Capability' in Chambers Europe, 2011.